Designation of Bevacizumab (Avastin) as an orphan drug - Roche Products Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2017G00043 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

 

DESIGNATION OF Bevacizumab (Avastin) AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate Bevacizumab (AVASTIN) as an orphan drug on 4 January 2017 for the treatment of malignant mesothelioma.

The dose form of Bevacizumab (AVASTIN) for this indication is concentrated injection.

The sponsor of Bevacizumab (AVASTIN) is Roche Products Pty Limited.

 

 

(Signed by)

 

Dr Anthony Gill

Delegate of the Secretary

4 January 2017

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.